PACTR202209521256638尚未招募3 期
Shortening Buruli Ulcer treatment: WHO recommended vs. a novel beta-lactam-containing therapy - Phase III evaluation in West Africa
niversity of Zaragoza0 个研究点目标入组 174 人开始时间: 2022年9月12日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 174
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 6 Year(s) 至 12 Year(s)（—）
- 性别
- All
入选标准
- •All patients (both genders) with a new Very Likely” or Likely” (as per World Health Organisation, WHO, scoring criteria) clinical BU diagnosis (all categories: I, II, III).(The WHO clinical diagnosis would be supported, as agreed, by the trial and reviewed by the local study technical expert panel.)
- •- Normal ECG (QTc = 450 ms) at baseline that give informed consent will be included in the study.
排除标准
- •Children < 5 years and adults >70 years.
- •Children in foster care.
- •Patients weighing less than 11 kilograms.
- •Pregnancy positive (urine test: beta-HCG positive).
- •Previous treatment of BU with at least one of the study drugs within 1 year before recruitment.
- •Patients with diagnosis of leprosy or tuberculosis disease.
- •Hypersensitivity to at least one of the study drugs or to any of the excipients.
- •History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to amoxicillin or another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).
- •History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid or rifampicin.
- •Patients with history of treatment with macrolide or quinolone antibiotics, anti-tuberculosis medication, or immuno-modulatory drugs including corticosteroids within one month before recruitment.
- •Patients currently receiving treatment with any drug likely to interact with the study medications, i.e. anticoagulants, cyclosporine, phenytoin or phenobarbitone. Users of oral contraceptives should be notified that such contraceptive is less reliable if taken with rifampicin; additional (mechanical) contraceptive methods will be discussed with the study participant (Appendix 5).
- •Patients with HIV co-infection.
- •Patients with QTc prolongation >450 ms on ECG or taking other medication known to prolong the QTc interval, such as quinolones. In this case, if suspected of BU disease, patients will be treated according to established local guidelines, i.e. with rifampicin and streptomycin for 8 weeks, if available, or will be referred for surgical treatment.
- •Patients unable to take oral medications or having gastrointestinal disease likely to interfere with drug absorption.
- •Patients with history or having current clinical signs of ascites, jaundice, myasthenia gravis, renal dysfunction (known or suspected), diabetes mellitus, and severe immune compromise, or evidence of tuberculosis, or leprosy; terminal i
研究者
相似试验
已完成
2 期
BURULICO Drug Trial Study Protocol: RCT SR8/SR4+CR4, GHANABuruli UlcerMycobacterium UlceransNCT00321178University Medical Center Groningen151
已完成
不适用
Heat treatment of Buruli ulcerISRCTN88392614niversity Hospital Heidelberg (Universitätsklinikum Heidelberg) (Germany)10
招募中
不适用
Adjuvant therapy of severe and/or refractory bullous pemphigoids with immunoadsorption by LIGASORB®, dapsone, prednisolone and topical mometasone fumarate (LiBPem-Study).L12.0Bullous pemphigoidDRKS00013775niversitätsklinikum Schleswig-Holstein Campus Lübeck10
已完成
3 期
Efficacy of optimized thiopurine therapy in ulcerative colitis.10017969Ulcerative ColitisNL-OMON47463Academisch Medisch Centrum59
招募中
不适用
A Survey of Midazolam in People with status epilepticusEpilepsyJPRN-jRCT2031210712Contact for Clinical Trial Information50